Lonvo-z

Rx-NTLA-2703NTLA/FDA decisionResearch

Intellia Therapeutics · hereditary angioedemaMar 10, 2027 target

Will the FDA approve Lonvo-z for hereditary angioedema?

Drug profile Company Event Gene editingNCT06634420

Primary source

YNTLA

NTLA-YES/ USDC

Outcome claim / Research candidate

NOT LISTED

Executable price

—

Change across observed prices in this window

Implied YES probability—Price-based, not a clinical forecast

Market not listed

No market price yet.

This program has no funded pool or observed trading history. Start with the evidence, or explore a clearly labeled scenario.

0 trading observationsNo live price feed

YES —NO —

This chart stays empty until observations exist. Research status is not an approval probability. A sandbox session creates a separate virtual price history.

Rx-NTLA-2703 / Evidence

Unlisted

Pool price—No deployed pool

Dated model P(YES)—No dated model artifact

Days to sponsor target128Date-only guidance

Source publishedSep 8, 2026

Research snapshotOct 28, 2026

FDA targetMar 10, 2027

Gene editingNCT06634420

A pool price describes trading inventory; a model estimates an outcome. Neither a live price nor a dated forecast is available for this unlisted catalyst.

Program overview

Sponsor filing describes an in vivo CRISPR therapy and a March 10, 2027 FDA target.

THERAPEUTIC AREAGene editing

DRUG / PROGRAMLonvo-z

INDICATIONhereditary angioedema

REGULATORY TARGETMarch 10, 2027

Agent model / unavailable

No reviewed probability or reasoning artifact is available. A neutral pool opening is not a clinical base rate.

What matters

Novel modality raises safety and interpretation risk; exact approved population must be pinned.
Approval, the stock price and commercial success are different outcomes. A claim only pays on its specified event.
Future program funding and tokenized financing require separate rights and contracts. An event claim gives no equity, royalty or drug IP.

Try virtual trading